<DOC>
	<DOCNO>NCT00988013</DOCNO>
	<brief_summary>This phase I study use Intensity Modulated Total Marrow Irradiation ( IM-TMI ) addition chemotherapy regimen preparation allogeneic stem cell transplant advance hematologic malignancy acute myeloid lymphoblastic leukemia , high grade non Hodgkin 's Hodgkin 's lymphoma , chronic myelogenous leukemia , plasma cell leukemia . Because subject participate study disease severe high risk relapse even transplant , investigator propose use chemotherapy regimen ( fludarabine/busulfan ) , name combination chemotherapy drug give patient prior transplantation donor stem cell , along intensity modulate radiation ( IM-TMI ) bone marrow . Total body irradiation ( TBI ) conjunction chemotherapy standard care pre-conditioning regimen prior bone marrow transplant ( BMT ) patient hematologic malignancy . However , TBI cause severe side effect due irradiation organs lenses eye , whole brain , lung , liver , kidney , heart , small bowel oral cavity . IM-TMI allows delivery adequate dos radiation bone marrow spar organ therefore limit radiation side effect . The irradiation , along receive chemotherapy drug suppress subject 's immune system kill tumor cell , also intensify effect condition regimen thus allow bone marrow transplantation great chance successful . No investigational drug use study . The investigational part study use intensity modulate total marrow irradiation instead conventional radiation . IMTMI deliver 99 % prescribed treatment target bone reduce dos radiation surround organ , receive conventional TBI , 29 % 65 % .</brief_summary>
	<brief_title>Intensity Modulated Total Marrow Irradiation ( IM-TMI ) Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Patients follow disease : Acute myeloid lymphoblastic leukemia first complete remission poor prognosis document failure response initial induction chemotherapy , cytogenetic , molecular study . Acute leukemia greater/equal second remission , partial remission chemotherapy . High grade non Hodgkin 's Hodgkin 's lymphoma marrow involvement resistant/ relapse second line therapy include high dose chemotherapy autologous SCT . CML advance blastic phase . Plasma cell leukemia . Age 1860 year . Karnofsky performance status 70 Adequate cardiac pulmonary function . Patients decrease LVEF le than/equal 40 % DLCO le than/equal 50 % predict require clearance cardiology pulmonary service , respectively , prior enrollment protocol . Serum creatinine less than/equal 1.5 mg/dL Creatinine Clearance great than/equal 50 ml/min . Serum bilirubin 2.0 mg/dl , SGPT le than/equal 3 time upper limit normal Life expectancy severely limited concomitant illness . Evidence chronic active hepatitis cirrhosis HIVpositive Patient pregnant Patient guardian able sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>total marrow irradiation</keyword>
	<keyword>intensity modulate radiation</keyword>
	<keyword>leukemia</keyword>
	<keyword>hematologic disease</keyword>
</DOC>